Oxford Covid vaccine produces 'strong' immune response among elderly

Grant Boone
October 28, 2020

AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK).

At the weekend, Johnson&Johnson, who is working with AstraZenaca in the USA, said the first batches of its shot could be ready to go in January.

"It is unlikely that we will have a single winning vaccine in the race against covid-19".

AstraZeneca said it was "encouraging to see immunogenicity responses were similar between older and younger adults".

It is considered one of the most promising and advanced in the world to combat the global pandemic, which has now claimed the lives of 1.1 million people.

"We do not know the efficacy at this point and that is why we are eagerly awaiting the phase-three trial results", she told Al Jazeera from Lucerne, Switzerland. He said that although the trials were on and those who were administered the vaccine found to have neutralising antibodies, they had evidence only for 56 days.

"The programme is progressing well [but] we're not there yet", Hancock said.

Samsung creates a 10,000 PPI OLED panel
As per the research, the first one, called red-green-blue OLED, has individual sub-pixels that contain only one colour of emitter. The reflecting layers allow for a much higher pixel density than ordinary RGB OLED on smartphones.

People aware of the results from so-called immunogenicity blood tests carried out on a subset of older participants say the findings echo data released in July.

The Phase I interim analysis data showed mRNA-1273 was generally well-tolerated in all age groups and induced rapid and strong immune responses against SARS-CoV-2 virus.

He also said that at present there is no vaccine in the world and that it is fortunate that trials are being done on Indian soil. Details of the results are expected to be published in a clinical journal, the FT said.

About a dozen, including the Oxford vaccine and U.S. biotech firm Moderna's candidate, have reached phase-three trials.

The two companies also announced that they had been greenlighted to resume their late-stage clinical trial into the vaccine.

On Tuesday, the Russian Direct Investment Fund, which finances the vaccine, said that accelerated registration would make Sputnik V "available globally in a shorter time frame than usual procedures".

This does not necessarily mean the vaccine, being developed alongside the University of Oxford, is safe and effective in older people - but it is promising news, given that the immune system weakens as a person grows older. "The World Health Organisation (WHO) itself has appreciated the state government's transparency in providing Covid statistics", he said.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER